Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (266)	7/25/2002 10:35:55 PM
From: Czechsinthemail	Respond to of 598

I'd have to agree that the conference call was very disappointing. There was precious little forward guidance apart from the news that they were planning to initiate Phase I in the UK during the 4Q on a compound that has large market opportunity. But without information about the indication, the target, or where their other preclinical compounds stand it makes the company much more of a black box. The ostensible reason for not disclosing more information was to maintain competitive advantage. That seems questionable to me, and it certainly puts an additional and unnecessary burden on investor trust by keeping investors even further out of the information loop. Developing companies need the collective trust and confidence of shareholders. One way to earn it is by consistently performing and delivering results. Unfortunately, for younger companies that can't reference a glowing history, it is necessary to create a compact with shareholders that bonds them with the company's development through a shared journey. Without communication, the journey isn't shared. Worse still, in the absence of positive communication, the void is easily filled with fears that no news is bad news. I hope they quickly reverse this new tight-lipped format. PS Based on the earlier guidance they gave, the launching of the new Phase I is a potentially big deal. Unfortunately, no details so no discussion.

To: scaram(o)uche who wrote (266)	7/26/2002 3:26:07 PM
From: JFitnich	Read Replies (2) \| Respond to of 598

Rick, Appreciate your comments and POV on TLRK. Look like the market agrees with your assessment of the call. I have not listened yet (tonight). I keep coming back to TLRK to look to add shares and keep passing. I can't get excited about T-67 and think that the HCC trial protocol (different dose) for the Phase 3 is rushed. As I see it, the Phase 3 rests on 3 options: (1) FDA signs off on Phase 1 trial w/ X (small) patients in HCC @ 250mg/m2 dose. If that flies, then Phase 3 can proceed. (2) FDA asks for another Phase 2 trial in HCC at the 250mg/m2, similar to the one just presented at ASCO (3) FDA OK's Phase 3 based on completed trials (Phase 1's - Non HCC) that already used the 250mg/m2 dose I have my doubts about 1 & 3 and I think another Phase 2 trial at the new dose is likely. That would push approval to 2005-2006. So…I guess I'm waiting for the FDA meeting. In short, I understand the company's need (& patients) to go rapidly, it just makes me cautious to add anymore at this point. I would love for something to come out of the oncogene program (bias…I own MEDX). This long-winded (and most likely error-filled) explanation is opinion only. I own TLRK (modest) JF P.S. If Mike M. is reading, congrats on the new bambino!